The pharmacokinetics and pharmacodynamics pathway of temsirolimus, an inhibitor of mTOR pathway used in the treatment of renal cell carcinoma and other types of tumors. Hypoxia inducible factor (HIF) pathway is constitutively active in renal cell carcinoma; HIF-alpha translation is under the control of mTOR pathway. Genetic variations can result in changes in drug availability and can cause differences in the response of the organism to the drug.